2025 Third Quarter Update
Capital Strategy
Nanochon has secured commitments to close oversubscribed convertible note, bringing our total capital raised to date to $11.3 million. While the majority of this bridge was filled by current investors, we’re thrilled to welcome a few new folks onto our cap table. Throughout the summer, Nanochon’s time and resources have been dedicated to launching our first in-human study. We’ve been working closely with our clinical advisors to select the right study sites and begin collaboration to obtain the necessary approvals to facilitate the trial seamlessly.
Commercial Strategy
The Nanochon team is building up our digital assets and we’re collaborating with graphic designers at TMG, who are creating a technical explainer video to narrate how Chondrograft addresses a market need. This piece will detail the problem/need and how our device addresses this, using animation to demonstrate the surgery and repair process. The video will be used for presentations at industry events and we look forward to sharing the final version with you soon!
As fall conference season commences, Nanochon looks forward to seeing our colleagues and partners once again at ICRS in Boston in October. Visit us at our booth number 30. We’re also thrilled to announce that our equine study will be presented during ICRS by Dr. Charlotte Barton of the Colorado State University College of Veterinary Medicine and Biomedical Sciences.
Clinical Strategy
Nanochon was granted approval for its first-in-human study by Health Canada in July and we are working hard to commence in Q4 2025, pending final ethics approval.